Evidence map›Paper›PMID 37842125›Full record

ArticleFrontiers in aging neuroscience2023

Multifactorial assessment of Parkinson's disease course and outcomes using trajectory modeling in a multiethnic, multisite cohort - extension of the LONG-PD study.

Bruce A Chase, Rejko Krueger, Lukas Pavelka, Sun Ju Chung, Jan Aasly, Efthimios Dardiotis, Ashvini P Premkumar, Bernadette Schoneburg, Ninith Kartha, Navamon Aunaetitrakul and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.Movement disorders : official journal of the Movement Disorder Society · 2024
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Bruce A ChaseHealth Information Technology, NorthShore University HealthSystem, Evanston, IL, United States.
Rejko KruegerTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg.
Lukas PavelkaTransversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Sun Ju ChungDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jan AaslyDepartment of Neurology, St. Olav's Hospital, Trondheim, Norway.
Efthimios DardiotisDepartment of Neurology, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Ashvini P PremkumarDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
Bernadette SchoneburgDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
Ninith KarthaDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
Navamon AunaetitrakulDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
Roberta FrigerioDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
Demetrius MaraganoreDepartment of Neurology, Tulane University, New Orleans, LA, United States.
Katerina MarkopoulouDepartment of Neurology, NorthShore University HealthSystem, Evanston, IL, United States.
NorthShore University HealthSystem · USLuxembourg Institute of Health · LUAsan Medical Center · KRNorwegian University of Science and Technology · NOTulane University · USUniversity Hospital of Larissa · GR

Funding

Wellcome Trust
6 · The paper itself

Abstract

Background: The severity, progression, and outcomes of motor and non-motor symptoms in Parkinson's disease (PD) are quite variable. Following PD cohorts holds promise for identifying predictors of disease severity and progression. Methods: PD patients ( Results: The best fitting models identified three groups. One showed a relatively benign, slowly progressing trajectory (Group 1), a second showed a moderate, intermediately progressing trajectory (Group 2), and a third showed a more severe, rapidly progressing trajectory (Group 3). Stable trajectory-group membership occurred relatively early in the disease course, 5 years after initial motor symptom. Predictors of intermediate and more severe trajectory-group membership varied across the single variable models and the multivariable model jointly considering UPDRS-III, H&Y and MMSE scores. In the multivariable model, membership in Group 2 (28.4% of patients), relative to Group 1 (50.5%), was associated with male sex, younger age-at-onset, fewer education-years, pesticide exposure, absence of reported head injury, and akinetic/rigid subtype at initial presentation. Membership in Group 3 (21.3%), relative to Group 1, was associated with older age-at-onset, fewer education-years, pesticide exposure, and the absence of a tremor-predominant subtype at initial presentation. Persistent freezing, persistent falls, and cognitive impairment occurred earliest and more frequently in Group 3, later and less frequently in Group 2, and latest and least frequently in Group 1. Furthermore, autonomic complications, dysphagia, and psychosis occurred more frequently in Groups 2 and 3 than in Group 1. Conclusion: Modeling disease course using multiple objective assessments over an extended follow-up duration identified groups that more accurately reflect differences in PD course, prognosis, and outcomes than assessing single parameters over shorter intervals.

Indexed as

disease outcomesgroup-based-trajectory modellongitudinal monitoringmotor symptomsnon-motor symptomsParkinson’s disease

Identifiers

PMID37842125
PMCPMC10569724
OpenAlexW4387099084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.